Real World Study of End-stage Liver Disease in China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorHuashan Hospital
About this trial
The aims of this study are exploring the current situation of end-stage liver disease in China, and the optimization of diagnosis and treatment. Liver cirrhosis often accompanied by a series of complications. Therefore, it is necessary to standardize the diagnosis and treatment of liver cirrhosis and its complications. End-stage liver disease mainly refers to the late stage of liver disease caused by various chronic liver damage. Its main feature is that liver function can not meet the physiological needs of human body. This study is a single-center, prospective and observational real-world study aimed at investigating and analyzing the current diagnosis and treatment of liver cirrhosis and end-stage liver disease in China.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Informed consent of patients.
Diagnosis of any of the following diseases: acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure and hepatocellular carcinoma (stage III-IV)
Disqualifiers
HIV antibody positive and AIDS patients
Serious psychiatric history, especially depression. Severe mental illness is defined as major depression or psychosis, suicide attempts, hospitalization due to mental illness or a period of disability due to mental illness.
Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.
Patients with other malignant tumors (excluding those cured).
Trial population
The population who were diagnosed of acute decompensation of cirrhosis, chronic and acute liver failure, chronic liver failure or hepatocellular carcinoma (stage III-IV)
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
No intervation
Other interventionNo intervation
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Patient died during follow-up
Death occurred during 3 year
Time frame
3 yearsSecondary outcomes
1
Major events occurred during follow-up
the major events including liver transplantation and the happening of serious complications
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov